BRPI0922650A2 - Composto, composição farmacêutica, uso de pelo menos um composto, métodos para tratar doenças, para diagnosticar nefropatia diabética, e para triar compostos, e, uso de sinaptopodina - Google Patents

Composto, composição farmacêutica, uso de pelo menos um composto, métodos para tratar doenças, para diagnosticar nefropatia diabética, e para triar compostos, e, uso de sinaptopodina

Info

Publication number
BRPI0922650A2
BRPI0922650A2 BRPI0922650A BRPI0922650A BRPI0922650A2 BR PI0922650 A2 BRPI0922650 A2 BR PI0922650A2 BR PI0922650 A BRPI0922650 A BR PI0922650A BR PI0922650 A BRPI0922650 A BR PI0922650A BR PI0922650 A2 BRPI0922650 A2 BR PI0922650A2
Authority
BR
Brazil
Prior art keywords
compound
compounds
diabetic nephropathy
sinaptopodin
pharmaceutical composition
Prior art date
Application number
BRPI0922650A
Other languages
English (en)
Inventor
Cravo Daniel
Hallakou-Bozec Sophie
Mesangeau Didier
Elbawab Samer
Original Assignee
Poxel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poxel filed Critical Poxel
Publication of BRPI0922650A2 publication Critical patent/BRPI0922650A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/10—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSTO, COMPOSIÇÃO FARMACÊUTICA, USO DE PELO MENOS UM COMPOSTO, MÉTODOS PARA TRATAR DOENÇAS, PARA DIAGNOSTICAR NEFROPATIA DIABÉTICA, E PARA TRIAR COMPOSTOS, E, USO DE SINAPTOPODINA. A invenção refere-se a compostos da fórmula (1) em que os radicais R1 a R6 têm o significado de acordo com a reivindicação 1, e/ou sais fisiologicamente aceitáveis do mesmos, para o tratamento profilático ou terapêutico e/ou monitoramento de condições fisiológicas e/ou patológicas que são associadas com a atividade de proteína cinase ativada por AMP (AMPK). Um outro objetivo da invenção diz respeito ao uso dos ditos compostos para realçar a homeostase da glicose, melhorar a podocitopatia e/ou diminuir a produção de espécies de oxigênio reativo (ROS). A invenção também refere-se a um método para diagnosticar nefropatia diabética in vitro e um método para triar compostos que reduzem a podocitopatia, em cada caso aplicando-se sinaptopodina como biomarcador.
BRPI0922650A 2008-12-12 2009-12-11 Composto, composição farmacêutica, uso de pelo menos um composto, métodos para tratar doenças, para diagnosticar nefropatia diabética, e para triar compostos, e, uso de sinaptopodina BRPI0922650A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08021618 2008-12-12
PCT/EP2009/066999 WO2010066901A2 (en) 2008-12-12 2009-12-11 Tetrahydrotriazine compounds for treating diseases associated with ampk activity

Publications (1)

Publication Number Publication Date
BRPI0922650A2 true BRPI0922650A2 (pt) 2017-07-11

Family

ID=42026760

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0922650A BRPI0922650A2 (pt) 2008-12-12 2009-12-11 Composto, composição farmacêutica, uso de pelo menos um composto, métodos para tratar doenças, para diagnosticar nefropatia diabética, e para triar compostos, e, uso de sinaptopodina

Country Status (12)

Country Link
US (1) US9035048B2 (pt)
EP (1) EP2367802B1 (pt)
JP (1) JP5485292B2 (pt)
CN (1) CN102245581A (pt)
AU (1) AU2009326965A1 (pt)
BR (1) BRPI0922650A2 (pt)
CA (1) CA2745854A1 (pt)
ES (1) ES2573266T3 (pt)
IL (1) IL212901A0 (pt)
MX (1) MX2011005644A (pt)
TW (1) TW201033182A (pt)
WO (1) WO2010066901A2 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2324126T3 (da) 2008-08-12 2014-06-16 Zinfandel Pharmaceuticals Inc FREMGANGSMÅDE TIL IDENTIFICERING AF Alzheimers SYGDOMSRISIKOFAKTORER
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
FR2948026B1 (fr) * 2009-07-17 2011-12-02 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine
FR2948027A1 (fr) 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
JP5707489B2 (ja) * 2010-06-09 2015-04-30 ポクセル・エスアーエスＰｏｘｅｌｓａｓ １型糖尿病の処置
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
LT2661266T (lt) 2011-01-07 2020-12-10 Anji Pharma (Us) Llc Gydimo būdai chemosensorinio receptoriaus ligando pagrindu
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
CN103501783A (zh) 2011-01-10 2014-01-08 金帆德尔制药股份有限公司 用于治疗阿尔茨海默病的方法和药物产品
CN104254325A (zh) 2012-01-06 2014-12-31 埃尔舍利克斯治疗公司 双胍组合物和治疗代谢性病症的方法
CN110693867A (zh) * 2012-01-06 2020-01-17 埃尔舍利克斯治疗公司 用于治疗代谢性病症的组合物和方法
WO2015002818A1 (en) * 2013-07-01 2015-01-08 Emory University Treating or preventing nephrogenic diabetes insipidus
WO2018079855A1 (ja) * 2016-10-31 2018-05-03 国立大学法人京都大学 がん細胞にプログラム細胞死を誘導するための医薬組成物
FR3068601B1 (fr) 2017-07-05 2021-02-19 Eric Joseph Marie Fulgence Janin Utilisation de l'imeglimine pour la prevention et/ou le traitement du carcinome hepatocellulaire
CN111163782A (zh) 2017-10-02 2020-05-15 普克塞尔公司 治疗射血分数保留型心力衰竭的方法
SG11202007172YA (en) * 2018-06-06 2020-08-28 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
CA3103324A1 (en) 2018-06-14 2019-12-19 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
JP2023526625A (ja) 2020-05-19 2023-06-22 キャリーオペ，インク． Ａｍｐｋアクチベーター
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629467A (en) * 1969-10-17 1971-12-21 Armour Pharma Pharmaceutical preparations containing a 2 4-diamino-6-substituted-s-triazine and methods of using same
WO1991001733A1 (fr) * 1989-08-09 1991-02-21 Nippon Shinyaku Co., Ltd. Remede
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
GB2397301A (en) * 2003-01-14 2004-07-21 Novo Pharmaceuticals Ltd De Substituted 1,3,5-triazine derivatives
US20060004005A1 (en) * 2003-09-25 2006-01-05 Sattigeri Viswajanani J Triazines derivatives as cell adhesion inhibitors
FR2896158B1 (fr) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'inhibiteurs de la hmg-coa reductase.
FR2896159B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.

Also Published As

Publication number Publication date
US9035048B2 (en) 2015-05-19
EP2367802B1 (en) 2016-04-20
MX2011005644A (es) 2011-06-16
IL212901A0 (en) 2011-07-31
EP2367802A2 (en) 2011-09-28
CA2745854A1 (en) 2010-06-17
CN102245581A (zh) 2011-11-16
US20110236317A1 (en) 2011-09-29
WO2010066901A3 (en) 2010-08-05
WO2010066901A2 (en) 2010-06-17
JP5485292B2 (ja) 2014-05-07
ES2573266T3 (es) 2016-06-06
JP2012511549A (ja) 2012-05-24
AU2009326965A1 (en) 2011-06-23
TW201033182A (en) 2010-09-16

Similar Documents

Publication Publication Date Title
BRPI0922650A2 (pt) Composto, composição farmacêutica, uso de pelo menos um composto, métodos para tratar doenças, para diagnosticar nefropatia diabética, e para triar compostos, e, uso de sinaptopodina
ECSP099414A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteína quinasa
BRPI0507442B8 (pt) método in vitro de diagnóstico de um indivíduo humano gestante como apresentando ou com uma propensão a desenvolver pré-eclâmpsia ou eclâmpsia
EP2344475A4 (en) QUINAZOLINONE, QUINOLONE AND RELATED ANALOGUES AS MODULATORS OF SIRTUINE
EA201070035A1 (ru) Модулирующие сиртуин соединения
GT200900095A (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hermatologicas.
BRPI0822162A2 (pt) Método para tratamento de doenças das unhas ou leito ungueal e composição farmacêutica para tratamento tópico de doença das unhas ou leito ungueal.
BR112013010015A2 (pt) aparelho e método para detecção não invasiva de doenças que afetam as propriedades estruturais em tecidos biológicos
WO2009134973A8 (en) Quinolines and related analogs as sirtuin modulators
BRPI0717697A2 (pt) composto, composição farmaceutica, uso do composto, método para tratar um paciente sofrendo de uma condição patológica ou uma doença e combinação de produtos
EA200901583A1 (ru) N-(2-(гетарил)арил)арилсульфонамиды и n-(2-(гетарил)гетарил)арилсульфонамиды
BRPI0908026B8 (pt) uso de rifaximina no tratamento de doenças do intestino
BRPI1005153A2 (pt) composto, composição farmacêutica, uso de um composto, metodo para tratar um indivíduo que sofre de uma condição patológica ou doença e produto de combinação
EA201070551A1 (ru) Сиртуинмодулирующие соединения
MY149316A (en) Sirtuin modulating imidazohiazole compounds
NO20080408L (no) Azaindazolforbindelser og anvendelse derav
CO6351803A2 (es) Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi)
WO2008144591A3 (en) Treatment of synucleinopathies
BR112013021125A2 (pt) método para regular os níveis de glicose no sangue, método para aumentar a secreção da insulina ou promover a liberação da insulina na corrente sanguínea, método para tratar uma doença ou condição, método para retardar o ínicio de uma doença ou condição de doença kit, composto de composição farmacêutica
BRPI0712322A2 (pt) compostos e combinações destes para a inibição da produção de beta-amilóide e métodos de uso dos mesmos
EA200901550A1 (ru) Способы лечения, диагностирования и выявления ассоциированных с fgf21 нарушений
MX2010012961A (es) Imidazopiridina y analogos relacionados como moduladores de sirtuina.
NO20092444L (no) Heteroarylamidderivater
BR112015007144A2 (pt) uso de masitinib para o tratamento de câncer em subpopulações de paciente identificadas usando fatores prognosticadores
BR112014031414A2 (pt) métodos de detectar doenças ou condições utilizando células doentes circulantes

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]